Related Experiment Video

Updated: Aug 20, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Uric acid in chronic heart failure

Wolfram Doehner1, Stefan D Anker

  • 1Division of Applied Cachexia Research, Department of Cardiology, Charite Medical School, Humboldt University, D-13353 Berlin, Germany. w.doehner@imperial.ac.uk

Seminars in Nephrology
|January 22, 2005
PubMed

Insights

Hyperuricemia, linked to the xanthine oxidase pathway, is a common issue in chronic heart failure (CHF). Targeting this pathway may improve CHF prognosis and symptoms.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Biochemistry

Background:

  • Chronic heart failure (CHF) pathophysiology involves complex neurohormonal, immune, and metabolic dysfunctions.
  • Hyperuricemia is a consistent metabolic abnormality observed in CHF patients.
  • The xanthine oxidase pathway is implicated in CHF symptoms and disease progression.

Purpose of the Study:

  • To discuss the significance of the xanthine oxidase metabolic pathway in CHF.
  • To review data on xanthine oxidase inhibition in CHF.
  • To explore the potential therapeutic benefits of targeting xanthine oxidase.

Main Methods:

  • Literature review of studies on xanthine oxidase pathway in CHF.
  • Analysis of data concerning hyperuricemia as a prognostic marker in CHF.
  • Examination of research on xanthine oxidase inhibitors' effects.

Main Results:

  • Hyperuricemia is an independent marker of poor prognosis in CHF.
  • The xanthine oxidase pathway contributes to CHF symptoms and progression.
  • Evidence suggests xanthine oxidase inhibition may offer therapeutic benefits.

Conclusions:

  • The xanthine oxidase pathway plays a crucial role in CHF.
  • Targeting xanthine oxidase presents a potential therapeutic strategy for CHF.
  • Further research into xanthine oxidase inhibition is warranted for CHF management.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...